Abbvie Share Price (NYSE: ABBV)

$210.64

▲

1.14

(0.54%)

Last updated on August 23, 2025 at 1:29 AM IST

$₹

Check the interactive Abbvie Stock chart to analyse performance

Abbvie stock performance

as on August 23, 2025 at 1:29 AM IST

Today's Low:$207.43
Today's High:$211.30
$210.64
1.52%
Downside
Day's Volatility :1.83%
Upside
0.31%
52 Weeks Low:$163.81
52 Weeks High:$218.66
$210.64
22.23%
Downside
52 Weeks Volatility :25.08%
Upside
3.67%

Abbvie Stock Returns

Period	Abbvie Inc	Sector (Health Care)	S&P500
3 Months	12.83%	5.0%	9.0%
6 Months	2.68%	-6.4%	5.9%
1 Year	6.07%	-11.5%	14.4%
3 Years	51.95%	4.5%	53.9%

Abbvie Inc Key Stats

Check Abbvie key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$209.5
Open	$210.475
Today's High	$211.3
Today's Low	$207.43
Market Capitalization	$369.5B
Today's Volume	$5.3M
52 Week High	$218.66
52 Week Low	$163.81
Revenue TTM	$58.3B
EBITDA	$28.1B
Earnings Per Share (EPS)	$2.09
PE Ratio	100.07
Dividend Yield	3.14%
Profit Margin	6.45%
Quarterly Earnings Growth YOY	-0.32%
Return On Equity TTM	112.85%

Stock Returns calculator for Abbvie Stock including INR - Dollar returns

The Abbvie stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Abbvie investment value today

Current value as on today

₹1,11,548

Returns

₹11,548

(+11.55%)

Returns from Abbvie Stock

₹7,267 (+7.27%)

Dollar Returns*

₹4,281 (+4.28%)

Indian investors sentiment towards Abbvie Stock

-15.12%

Period: Jul 23, 2025 to Aug 22, 2025. Change in 30 Days versus previous period

Investment in Abbvie Shares from India has dropped by -15.12% over the past 30 days, indicating reduced transactional activity.

-3%

Period: Jul 23, 2025 to Aug 22, 2025. Change in 30 Days versus previous period

Search interest for Abbvie Stock from India on INDmoney has decreased by -3% in the last 30 days, reflecting a downward trend in search activity.

Indian Mutual Funds that invest in Abbvie Stock

Name	Shares Held	Change in Shares	% of Assets
Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund Direct Growth	2792	0.00	2.79%
Motilal Oswal S&P 500 Index Fund Direct Growth	14278	-629.95	0.62%

Global Institutional Holdings in Abbvie Inc

Name
Holdings %
Name
Holdings %
Vanguard Group Inc
10.04%
BlackRock Inc
8.26%
State Street Corp
4.53%
JPMorgan Chase & Co
3.10%
Morgan Stanley - Brokerage Accounts
2.33%
Geode Capital Management, LLC
2.17%

Analyst Recommendation on Abbvie Stock

Rating

Trend

Buy

65%Buy

34%Hold

0%Sell

Based on 35 Wall street analysts offering stock ratings for Abbvie(by analysts ranked 0 to 5 stars)

Abbvie Share Price Target

What analysts predicted

Upside of 1.96%

Target:

$214.77

Current:

$210.64

Abbvie share price target is $214.77, a slight Upside of 1.96% compared to current price of $210.64 as per analysts' prediction.

Abbvie Stock Insights

Price Movement
In the last 1 month, ABBV stock has moved up by 12.0%
Increasing Revenue
Abbvie Inc has seen a positive trend in its revenue over the past two quarters. It increased from $13.34 billion to $15.42 billion, representing an average growth of 13.5% each quarter.
Decreasing Net Profit
Abbvie Inc's net profit has decreased for the last two quarters, falling from $1.28 billion to $944 million. This represents an average decline of 26.6% per quarter.
ABBV vs JNJ (1 yr)
In the last 1 year, Johnson & Johnson has given 10.3% return, outperforming this stock by 3.6%
Price to Sales
Abbvie Inc has a Price-to-Sales Ratio of 6.4, meaning investors are willing to pay $6.4 for every $1 of sales the company generates. In comparison, Johnson & Johnson has a lower Price-to-Sales Ratio of 4.8, indicating that investors are paying less per dollar of sales for that company.

Abbvie Inc Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$33.3B	↑ 1.57%
Net Income	$7.9B	↑ 38.6%
Net Profit Margin	23.69%	↑ 6.33%

	FY20	Y/Y Change
Revenue	$45.8B	↑ 37.69%
Net Income	$4.6B	↓ 41.44%
Net Profit Margin	10.08%	↓ 13.61%

	FY21	Y/Y Change
Revenue	$56.2B	↑ 22.69%
Net Income	$11.5B	↑ 150.04%
Net Profit Margin	20.54%	↑ 10.46%

	FY22	Y/Y Change
Revenue	$58.1B	↑ 3.3%
Net Income	$11.8B	↑ 2.55%
Net Profit Margin	20.39%	↓ 0.15%

	FY23	Y/Y Change
Revenue	$54.3B	↓ 6.44%
Net Income	$4.9B	↓ 58.91%
Net Profit Margin	8.95%	↓ 11.44%

	FY24	Y/Y Change
Revenue	$56.3B	↑ 3.71%
Net Income	$4.3B	↓ 12.03%
Net Profit Margin	7.59%	↓ 1.36%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$12.3B	↓ 13.92%
Net Income	$1.4B	↑ 66.55%
Net Profit Margin	11.12%	↑ 5.37%

	Q2 FY24	Q/Q Change
Revenue	$14.5B	↑ 17.48%
Net Income	$1.4B	↑ 0.07%
Net Profit Margin	9.47%	↓ 1.65%

	Q3 FY24	Q/Q Change
Revenue	$14.5B	↓ 0.01%
Net Income	$1.6B	↑ 13.94%
Net Profit Margin	10.8%	↑ 1.33%

	Q4 FY24	Q/Q Change
Revenue	$15.1B	↑ 4.44%
Net Income	$-22.0M	↓ 101.41%
Net Profit Margin	-0.15%	↓ 10.95%

	Q1 FY25	Q/Q Change
Revenue	$13.3B	↓ 11.65%
Net Income	$1.3B	↓ 5945.45%
Net Profit Margin	9.64%	↑ 9.79%

	Q2 FY25	Q/Q Change
Revenue	$15.4B	↑ 15.59%
Net Income	$944.0M	↓ 26.59%
Net Profit Margin	6.12%	↓ 3.52%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$25.8B	↑ 3.16%

	FY20	Y/Y Change
Profit	$30.4B	↑ 17.77%

	FY21	Y/Y Change
Profit	$38.8B	↑ 27.4%

	FY22	Y/Y Change
Profit	$40.6B	↑ 4.87%

	FY23	Y/Y Change
Profit	$33.9B	↓ 16.58%

	FY24	Y/Y Change
Profit	$39.4B	↑ 16.3%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$8.2B	↓ 4.43%

	Q2 FY24	Q/Q Change
Profit	$10.3B	↑ 24.88%

	Q3 FY24	Q/Q Change
Profit	$10.2B	↓ 0.12%

	Q4 FY24	Q/Q Change
Profit	$10.7B	↑ 4.47%

	Q1 FY25	Q/Q Change
Profit	$9.3B	↓ 12.75%

	Q2 FY25	Q/Q Change
Profit	$13.0B	↑ 39.39%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$13.3B	↓ 0.77%
Investing Cash Flow	$596.0M	↓ 159.24%
Financing Cash Flow	$18.7B	↓ 229.95%

	FY20	Y/Y Change
Operating Cash Flow	$17.6B	↑ 32.0%
Investing Cash Flow	$-37.6B	↓ 6401.51%
Financing Cash Flow	$-11.5B	↓ 161.48%

	FY21	Y/Y Change
Operating Cash Flow	$22.8B	↑ 29.5%
Investing Cash Flow	$-2.3B	↓ 93.76%
Financing Cash Flow	$-19.0B	↑ 65.54%

	FY22	Y/Y Change
Operating Cash Flow	$24.9B	↑ 9.51%
Investing Cash Flow	$-623.0M	↓ 73.42%
Financing Cash Flow	$-24.8B	↑ 30.27%

	FY23	Y/Y Change
Operating Cash Flow	$22.8B	↓ 8.44%
Investing Cash Flow	$-2.0B	↑ 222.47%
Financing Cash Flow	$-17.2B	↓ 30.56%

	FY24	Y/Y Change
Operating Cash Flow	$18.8B	↓ 17.66%
Investing Cash Flow	$-20.8B	↑ 936.34%
Financing Cash Flow	$-5.2B	↓ 69.74%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$4.0B	↓ 15.0%
Investing Cash Flow	$-9.6B	↑ 1098.5%
Financing Cash Flow	$10.8B	↓ 343.18%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$2.3B	↓ 43.79%
Investing Cash Flow	$-1.1B	↓ 88.51%
Financing Cash Flow	$-6.1B	↓ 156.35%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$5.4B	↑ 139.85%
Investing Cash Flow	$-8.3B	↑ 649.18%
Financing Cash Flow	$-3.1B	↓ 49.61%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$7.0B	↑ 29.39%
Investing Cash Flow	$-1.9B	↓ 77.3%
Financing Cash Flow	$-6.9B	↑ 123.34%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$1.6B	↓ 76.8%
Investing Cash Flow	$-735.0M	↓ 60.78%
Financing Cash Flow	$-1.3B	↓ 81.66%

Abbvie Technicals Summary

Sell

Neutral

Buy

Abbvie is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Abbvie Inc Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Abbvie Inc	9.97%	2.68%	6.07%	51.95%	121.72%
Eli Lilly And Company	-11.19%	-19.51%	-25.53%	122.5%	374.5%
Johnson & Johnson	5.86%	9.32%	9.06%	8.11%	17.65%
Merck & Co. Inc.	2.4%	-5.63%	-26.13%	-4.31%	0.83%
Novo Nordisk A/s	-20.81%	-38.78%	-59.51%	0.81%	68.15%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Abbvie Inc	100.07	100.07	0.44	11.97	1.13	0.09	0.03	-0.1
Eli Lilly And Company	46.36	46.36	1.02	22.86	0.86	0.17	0.01	20.38
Johnson & Johnson	19.16	19.16	1.09	10.85	0.3	0.08	0.03	32.6
Merck & Co. Inc.	13.26	13.26	0.83	8.93	0.35	0.13	0.04	19.57
Novo Nordisk A/s	13.96	13.96	1.6	24.84	0.79	0.22	0.03	37.82

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Abbvie Inc	Buy	$369.5B	121.72%	100.07	6.45%
Eli Lilly And Company	Buy	$636.3B	374.5%	46.36	25.91%
Johnson & Johnson	Buy	$430.9B	17.65%	19.16	25.0%
Merck & Co. Inc.	Buy	$215.0B	0.83%	13.26	25.79%
Novo Nordisk A/s	Buy	$239.5B	68.15%	13.96	35.61%

Abbvie Dividend announcements

Abbvie Dividends September, 2025
In the quarter ending September,2025. Abbvie has declared dividend of $1.64

About Abbvie Inc

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta/Venclyxto to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic to treat neurologic diseases; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duopa and Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; and Qulipta for episodic and chronic migraine, as well as other neuroscience products. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Organization	Abbvie
Employees	55000
CEO	Mr. Scott T. Reents
Industry	Health Technology

Key Management of Abbvie Inc

Name	Title
Mr. Scott T. Reents	Executive VP & CFO
Dr. Azita Saleki-Gerhardt Ph.D.	Executive VP & COO
Mr. Jeffrey Ryan Stewart	Executive VP & Chief Commercial Officer
Dr. Roopal Thakkar M.D.	Executive VP of Research and Development & Chief Scientific Officer
Ms. Elizabeth Shea	Senior Vice President of Investor Relations
Mr. Perry C. Siatis	Executive VP, General Counsel & Secretary
Mr. Demetris D. Crum	Executive VP & Chief Human Resources Officer
Mr. Wulff-Erik von Borcke	Senior VP & President of Oncology
Dr. Nicholas J. Donoghoe M.D.	Executive VP and Chief Business & Strategy Officer
Ms. Tracie Haas	Senior Vice President of Corporate Affairs

Important FAQs about investing in ABBV Stock from India :

What is Abbvie share price today?

Abbvie share price today is $210.64 as on August 23, 2025 at 1:29 AM IST at the close of the market. Abbvie share today touched a day high of $211.30 and a low of $207.43.

What is the 52 week high and 52 week low for Abbvie share?

Abbvie share touched a 52 week high of $218.66 and a 52 week low of $163.81. Abbvie stock price today i.e. August 23, 2025 at 1:29 AM IST is closed at $210.64, lower by 3.67% versus the 52 week high.

How to invest in Abbvie Stock (ABBV) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Abbvie on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Abbvie Shares that will get you 0.0071 shares as per Abbvie share price of $210.64 per share as on August 23, 2025 at 1:29 AM IST.

What is the minimum amount required to buy Abbvie Stock (ABBV) from India?

Indian investors can start investing in Abbvie (ABBV) shares with as little as ₹87.521 or $1 (as of August 23, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹875.21 in Abbvie stock (as per the Rupee-Dollar exchange rate as on August 23, 2025). Based on Abbvie share’s latest price of $210.64 as on August 23, 2025 at 1:29 AM IST, you will get 0.0475 shares of Abbvie. Learn more about fractional shares .

What are the returns that Abbvie has given to Indian investors in the last 5 years?

Abbvie stock has given 121.72% share price returns and 18.0% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your US Stock Investments?